<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655810</url>
  </required_header>
  <id_info>
    <org_study_id>201102160</org_study_id>
    <nct_id>NCT01655810</nct_id>
  </id_info>
  <brief_title>Vitamin D, Cardiovascular Disease, and African Americans</brief_title>
  <official_title>Vitamin D and Early Markers of Cardiovascular Disease in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      African-Americans have higher rates of cardiovascular disease morbidity and mortality, as
      well as vitamin D deficiency. Multiple observational studies have demonstrated an increased
      risk of vitamin D deficiency in African Americans with type 2 diabetes and correlation
      between cardiovascular disease and vitamin D levels; however, there is a lack of
      interventional trials exploring this connection. The objective of this proposal is to address
      the hypothesis that treatment of vitamin D deficiency in African Americans with type 2
      diabetes will improve subclinical markers of cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a double blinded, randomized controlled trial of vitamin D3
      supplementation, 4,000 international units per day versus 600 international units per day,
      for one year to determine the effects on markers of subclinical cardiovascular disease in
      African Americans with type 2 diabetes and vitamin D deficiency. Outcome assessment will
      focus on changes in carotid intima-medial thickness (CIMT - ultrasound of the thickness of
      blood vessels in the neck), as well as markers of systemic inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in carotid intima-medial thickness</measure>
    <time_frame>0, 6, and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systemic inflammatory markers</measure>
    <time_frame>0, 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum calcium</measure>
    <time_frame>0, 1, 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Calcium</measure>
    <time_frame>0, 1, 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D 4000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D 600 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Multivitamin containing cholecalciferol 4000 units orally daily</description>
    <arm_group_label>Vitamin D 4000 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Multivitamin containing cholecalciferol 600 units orally daily</description>
    <arm_group_label>Vitamin D 600 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>500 mg orally twice daily</description>
    <arm_group_label>Vitamin D 4000 IU</arm_group_label>
    <arm_group_label>Vitamin D 600 IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  African Americans of both genders

          -  Age 50-70 years

          -  Type 2 diabetes (A1C &lt; 9.0%), on stable therapy with oral medications, insulin, or a
             combination

          -  25(OH)D level &lt; 20 ng/ml

          -  BP &lt; 140/90 mmHg; LDL &lt; 140 mg/dl

        Exclusion Criteria:

          -  Pregnancy

          -  Cardiovascular disease

          -  Stage 3 or worse chronic kidney disease

          -  High urine or serum calcium or history of recurrent kidney stones

          -  Unstable medical conditions or major systemic diseases such as malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Bernal-Mizrachi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>August 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

